Department of Clinical Microbiology, Royal University Hospital and the Saskatchewan Health Authority, Saskatoon, Saskatchewan, Canada.
Departments of Microbiology and Immunology, Pathology and Ophthalmology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
PLoS One. 2019 Jan 10;14(1):e0210154. doi: 10.1371/journal.pone.0210154. eCollection 2019.
Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis are prevalent bacterial causes of swine infections. Morbidity, mortality and positively impacting the financial burden of infection occurs with appropriate antimicrobial therapy. Increasing antimicrobial resistance complicates drug therapy and resistance prevention is now a necessity to optimize therapy and prolong drug life. Mutant bacterial cells are said to arise spontaneously in bacterial densities of 107-109 or greater colony forming units/ml. Antibiotic drug concentration inhibiting growth of the least susceptible cell in these high density populations has been termed the mutant prevention concentration (MPC). In this study MPC and minimum inhibitory concentration (MIC) values of ceftiofur, enrofloxacin, florfenicol, tilmicosin and tulathromycin were determined against the swine pathogens A. pleuropneumoniae, P.multocida and S. suis. The following MIC90/MPC90 values (mg/L) for 67 A. pleuropneumoniae and 73 P. multocida strains respectively were as follows: A. pleuropneumoniae 0.031/0.5, ≤0.016/0.5, 0.5/2, 4/32, 2/32; P. multocida 0.004/0.25, 0.016/0.125, 0.5/0.5, 8/16, 0.5/1. For 33 S. suis strains, MIC90 values (mg/L) respectively were as follows: 1, 0.25, 4, ≥8 and ≥8. A total of 16 S. suis strains with MIC values of 0.063-0.5 mg/L to ceftiofur and 0.25-0.5 mg/L to enrofloxacin were tested by MPC; MPC values respectively were 0.5 and 1 mg/L respectively. MPC concentrations provide a dosing target which may serve to reduce amplification of bacterial subpopulations with reduced antimicrobial susceptibility. Drug potency based on MIC90 values was ceftiofur > enrofloxacin >florfenicol = tulathromycin > tilmicosin; based on MPC90 values was enrofloxacin > ceftiofur > tulathromycin > florfenicol ≥ tilmicosin.
猪传染性胸膜肺炎放线杆菌、多杀性巴氏杆菌和猪链球菌是猪感染的常见细菌性病原体。适当的抗菌治疗可降低发病率和死亡率,并减轻感染的经济负担。抗菌药物耐药性的增加使药物治疗变得复杂,因此耐药性预防已成为优化治疗和延长药物寿命的必要措施。据报道,突变细菌细胞会在细菌密度为 107-109 或更高的菌落形成单位/ml 时自发出现。抗生素药物浓度抑制这些高密度群体中最不敏感细胞生长的浓度被称为突变预防浓度(MPC)。在这项研究中,测定了头孢噻呋、恩诺沙星、氟苯尼考、替米考星和泰拉霉素对猪病原体胸膜肺炎放线杆菌、多杀性巴氏杆菌和猪链球菌的 MPC 和最小抑菌浓度(MIC)值。以下是 67 株胸膜肺炎放线杆菌和 73 株多杀性巴氏杆菌的 MIC90/MPC90 值(mg/L):胸膜肺炎放线杆菌分别为 0.031/0.5、≤0.016/0.5、0.5/2、4/32、2/32;多杀性巴氏杆菌分别为 0.004/0.25、0.016/0.125、0.5/0.5、8/16、0.5/1。对于 33 株猪链球菌,MIC90 值(mg/L)分别为 1、0.25、4、≥8 和≥8。共对 16 株对头孢噻呋 MIC 值为 0.063-0.5mg/L 且对恩诺沙星 MIC 值为 0.25-0.5mg/L 的猪链球菌进行了 MPC 检测;MPC 值分别为 0.5 和 1mg/L。MPC 浓度提供了一个给药目标,可能有助于减少具有较低抗菌敏感性的细菌亚群的扩增。基于 MIC90 值的药物效力分别为头孢噻呋>恩诺沙星>氟苯尼考=泰拉霉素>替米考星;基于 MPC90 值的药物效力分别为恩诺沙星>头孢噻呋>泰拉霉素>氟苯尼考≥替米考星。